[go: up one dir, main page]

MX2017011732A - Proteínas de fusión que comprenden glicoproteínas de la superficie del virus alfa modificado y antígeno asociado al tumor y métodos de los mismos. - Google Patents

Proteínas de fusión que comprenden glicoproteínas de la superficie del virus alfa modificado y antígeno asociado al tumor y métodos de los mismos.

Info

Publication number
MX2017011732A
MX2017011732A MX2017011732A MX2017011732A MX2017011732A MX 2017011732 A MX2017011732 A MX 2017011732A MX 2017011732 A MX2017011732 A MX 2017011732A MX 2017011732 A MX2017011732 A MX 2017011732A MX 2017011732 A MX2017011732 A MX 2017011732A
Authority
MX
Mexico
Prior art keywords
fusion proteins
modified alpha
alpha virus
tumor
methods
Prior art date
Application number
MX2017011732A
Other languages
English (en)
Inventor
Babad Jeffrey
Martina Pola Elin
Leonardi Peter
Original Assignee
Omnicyte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omnicyte filed Critical Omnicyte
Publication of MX2017011732A publication Critical patent/MX2017011732A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a proteínas de fusión que comprenden una o más glicoproteínas de la superficie del virus alfa modificado y uno o más antígenos específicos del tumor. También se describen proteínas de fusión que comprenden una o más glicoproteínas de la superficie del virus alfa modificado y uno o más antígenos virales específicos. También se describen proteínas de fusión que comprenden una o más glicoproteínas de la superficie del virus alfa modificado. También se refiere a métodos para activar el sistema inmune en pacientes con cáncer para infiltrar y eliminar células tumorales o células infectadas con un virus latente. La presente descripción proporciona una tecnología de plataforma que estimula una respuesta inmune más rápida, más amplia y más fuerte usando las proteínas de fusión.
MX2017011732A 2015-03-18 2016-03-18 Proteínas de fusión que comprenden glicoproteínas de la superficie del virus alfa modificado y antígeno asociado al tumor y métodos de los mismos. MX2017011732A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562134933P 2015-03-18 2015-03-18
PCT/US2016/023203 WO2016149643A2 (en) 2015-03-18 2016-03-18 Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof

Publications (1)

Publication Number Publication Date
MX2017011732A true MX2017011732A (es) 2018-08-15

Family

ID=56919485

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011732A MX2017011732A (es) 2015-03-18 2016-03-18 Proteínas de fusión que comprenden glicoproteínas de la superficie del virus alfa modificado y antígeno asociado al tumor y métodos de los mismos.

Country Status (12)

Country Link
US (3) US10660948B2 (es)
EP (1) EP3270958A4 (es)
JP (1) JP6921053B2 (es)
KR (1) KR20170121301A (es)
CN (2) CN107530410B (es)
AU (2) AU2016232771B2 (es)
BR (1) BR112017019776B1 (es)
CA (1) CA2979697A1 (es)
HK (1) HK1248610A1 (es)
MX (1) MX2017011732A (es)
RU (1) RU2017132190A (es)
WO (1) WO2016149643A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017019776B1 (pt) * 2015-03-18 2020-07-28 Omnicyte proteínas de fusão que compreendem glicoproteínas de superfície de alfavírus modificadas e antígeno associado a tumor e métodos dos mesmos
WO2018161092A1 (en) * 2017-03-03 2018-09-07 New York University Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins
EP3762023A4 (en) 2018-03-05 2021-12-29 New York University Induction and enhancement of antitumor immunity involving sindbis virus vectors expressing immune checkpoint proteins
CN110856724B (zh) * 2018-08-24 2022-05-27 杭州康万达医药科技有限公司 包含核酸及car修饰的免疫细胞的治疗剂及其应用
WO2020239118A1 (zh) * 2019-05-31 2020-12-03 广州威溶特医药科技有限公司 M1病毒变异体及其应用
WO2025106748A1 (en) * 2023-11-15 2025-05-22 Genvivo, Inc. Compositions and methods for therapeutic delivery

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726288A (en) * 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
WO1992005248A1 (en) * 1990-09-26 1992-04-02 Bristol-Myers Squibb Company Human papilloma viral protein expression for use in vaccine compositions
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
HUP0003601A3 (en) * 1997-08-05 2003-03-28 Stressgen Biotechnologies Corp Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins
US6168932B1 (en) * 1998-07-13 2001-01-02 Parker Hughes Institute Recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
CA2490384A1 (en) 2002-06-25 2003-12-31 Sekisui Chemical Co., Ltd. Expression vector, host, fused protein, process for producing fused protein and process for producing protein
EP1545610A4 (en) * 2002-09-06 2006-11-08 Mannkind Corp EPITOPE SEQUENCES
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
CN100528230C (zh) * 2003-02-19 2009-08-19 台桂香 重组人muc1-mbp融合蛋白抗肿瘤疫苗及生产工艺
US7381794B2 (en) * 2004-03-08 2008-06-03 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
CN100342017C (zh) * 2004-05-10 2007-10-10 中国医学科学院肿瘤医院肿瘤研究所 基因重组趋化抗原疫苗
AU2006302794B2 (en) * 2005-02-15 2011-08-04 Children's Hospital, Inc. New live virus vaccines
PL1923463T3 (pl) 2005-08-09 2012-02-29 Oncotherapy Science Inc Peptyd antygenowy do odrzucania raka pochodzący z glipikan-3 (GPC3) do zastosowania u HLA-A2-pozytywnego pacjenta i środek farmaceutyczny zawierający antygen
JP5137168B2 (ja) 2006-02-27 2013-02-06 独立行政法人科学技術振興機構 安定同位体標識脂肪族アミノ酸、その標的蛋白質への組み込み方法並びに蛋白質のｎｍｒ構造解析方法
ES2702274T3 (es) * 2009-07-24 2019-02-28 Immune Design Corp Vectores lentivirales no integrantes
US9393299B2 (en) 2009-08-07 2016-07-19 Transgene S.A. Composition for treating HBV infection
CA2826920A1 (en) * 2011-02-15 2012-08-23 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
TWI676636B (zh) * 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
BR112017019776B1 (pt) * 2015-03-18 2020-07-28 Omnicyte proteínas de fusão que compreendem glicoproteínas de superfície de alfavírus modificadas e antígeno associado a tumor e métodos dos mesmos

Also Published As

Publication number Publication date
AU2021269306A1 (en) 2021-12-09
US20180243389A1 (en) 2018-08-30
RU2017132190A3 (es) 2019-08-30
JP2018509937A (ja) 2018-04-12
RU2017132190A (ru) 2019-04-18
US10660948B2 (en) 2020-05-26
AU2016232771B2 (en) 2021-08-19
WO2016149643A2 (en) 2016-09-22
US12133885B2 (en) 2024-11-05
CN114262380A (zh) 2022-04-01
CA2979697A1 (en) 2016-09-22
AU2016232771A1 (en) 2017-10-05
JP6921053B2 (ja) 2021-08-18
EP3270958A4 (en) 2018-11-14
HK1248610A1 (zh) 2018-10-19
BR112017019776B1 (pt) 2020-07-28
CN107530410B (zh) 2021-11-09
US11471518B2 (en) 2022-10-18
BR112017019776A2 (pt) 2018-05-22
US20210077600A1 (en) 2021-03-18
WO2016149643A3 (en) 2016-12-01
US20230181706A1 (en) 2023-06-15
KR20170121301A (ko) 2017-11-01
EP3270958A2 (en) 2018-01-24
CN107530410A (zh) 2018-01-02
AU2021269306B2 (en) 2025-03-06

Similar Documents

Publication Publication Date Title
MX2017011732A (es) Proteínas de fusión que comprenden glicoproteínas de la superficie del virus alfa modificado y antígeno asociado al tumor y métodos de los mismos.
UY36538A (es) Anticuerpos humanos contra la glicoproteína del virus del ébola
MX2017008186A (es) Anticuerpos humanos para la hemaglutinina de influenza.
MX2021003175A (es) Vacuna contra el virus de la peste porcina africana.
CL2024001715A1 (es) Anticuerpo aislado que se une a la proteína e del virus del dengue; y uso.
CO2018007203A2 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
PE20171133A1 (es) Particulas tipo virus modificadas de cmv
UY35964A (es) Anticuerpos humanos para pd?1
MX2022006004A (es) Proteinas de fusion inmunomoduladoras y usos de las mismas.
BR112019010275A2 (pt) adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano
MA49874A (fr) Vecteurs hvt recombinants exprimant de multiples antigènes de pathogènes aviaires, et vaccins les contenant
IL261354A (en) Human cancer cells comprising recombinant polynucleotides encoding human leukocyte antigen (hla) genes compositions comprising same and uses thereof
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
EA201691631A1 (ru) Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
EP4070818A3 (en) Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
MX383596B (es) Moleculas biespecificas que son inmunorreactivas con celulas efectoras inmunes que expresan un receptor activador y un antigeno expresado por una celula infectada por un virus y usos de las mismas.
MX383507B (es) Antígenos del virus de la inmunodeficiencia humana, vectores, composiciones y métodos de uso de estos.
AR104604A1 (es) ANTICUERPOS ANTI-FcRn
MX2018004121A (es) Receptores de antigeno y usos de los mismos.
BR112018073238A2 (pt) vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer
CO2017007105A2 (es) Nuevos virus de tilapia
EA201792058A1 (ru) Виротерапия комбинацией антител
IL281730A (en) Combinations of oncolytic vaccinia virus and immune checkpoint inhibitors for treating cancer, and pharmaceutical compositions comprising such combinations
BR112018073007A2 (pt) terapia de combinação inicial:reforço
MX2016014868A (es) Metodos para secar por congelacion y rehidratar productos biologicos.